ESMO awards its first fellowship to support digital and computational pathology
The recipient, Balazs Acs from Karolinska Institutet, will conduct a two-year project to transform the manual aspects of breast cancer pathology into quantitative ones
A toolkit to address disparities in digitally enabled oncology trials
An initiative fosters inclusive research by improving patient access and participation in cancer research
AI and remote monitoring are shaping a new patient journey in oncology
Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting
Lamarca: “Understanding the problem is the first step to solving it”
Career growth is a step-by-step journey, built on resilience, clarity, and the ability to face challenges head-on - because success never happens overnight
Cancer Intelligence (eHealth, Telehealth Technology, BIG Data)
Will AI reduce or increase inequities in cancer care?
While the use of artificial intelligence systems is expanding in oncology, ethical issues including biases introduced in care delivery and uneven access to technology raise concerns about whether some patients may be left behind
Next-generation CAR-T cells are in the pipeline
Novel approaches are being tested to overcome current challenges in the use of cellular therapies such as high toxicity and a complex manufacturing process
The updated ESMO-MCBS captures the evolving treatment landscape and patient priorities
The ESMO-Magnitude of Clinical Benefit Scale has been enhanced to address critical aspects of modern oncology trials, such as novel study designs, quality of life and long-term survival benefits
Pan-cancer AI model shows to predict 30-day mortality in patients with advanced cancer
In a study, a machine learning approach outperformed cancer-specific models and revealed universal biomarkers to guide end-of-life care decisions
Data supports the use of an electric-based therapy combined to standard treatment in locally advanced pancreatic adenocarcinoma
Quality of life and pain management data adds to efficacy results of combining TTFields with gemcitabine and nab-paclitaxel as a potential new option of care
Target-led treatments for lung cancer – are they moving to the next level?
Antibody–drug conjugates may represent a step up from existing therapeutic options, but further optimisation and biomarker analyses are required.